Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$272.82 -3.85 (-1.39%)
As of 01:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Illumina - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
6
Buy
10

Based on 18 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 2 have given a sell rating, 6 have given a hold rating, and 10 have given a buy rating for ILMN.

Consensus Price Target

$225.94
-17.18% Downside
According to the 18 analysts' twelve-month price targets for Illumina, the average price target is $225.94. The highest price target for ILMN is $310.00, while the lowest price target for ILMN is $113.00. The average price target represents a forecasted downside of -17.18% from the current price of $272.82.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
10/13/25 to 10/13/26
1 Month Ago
9/13/25 to 9/13/26
3 Months Ago
7/15/25 to 7/15/26
1 Year Ago
10/13/24 to 10/13/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$225.94$199.13$153.56$120.24
Forecasted Upside-17.18% Downside-3.55% Downside-17.95% Downside26.52% Upside
Consensus RatingHoldHoldHoldHold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaHealthcare CompaniesBroader Market
Consensus Rating Score
2.44
2.32
2.53
Consensus RatingHoldHoldModerate Buy
Predicted Upside-19.69% Downside1,031.70% Upside19.24% Upside
News Sentiment Rating
Positive News

See Recent ILMN News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/7/2026
Barclays PLC logo
Barclays
3 of 5 stars
Luke Sergott
Luke Sergott
5 of 5 stars
Boost TargetUnderweight$160.00 ➝ $200.00-26.88%
10/5/2026
Dan Leonard
Dan Leonard
Not Rated
Boost TargetOutperform$230.00 ➝ $310.00+12.36%
10/1/2026
Guggenheim logo
Guggenheim
5 of 5 stars
Subbu Nambi
Subbu Nambi
5 of 5 stars
Boost TargetBuy$226.00 ➝ $305.00+12.33%
9/29/2026Boost TargetOutperform$220.00 ➝ $300.00+11.63%
9/28/2026Boost TargetOverweight$225.00 ➝ $305.00+12.96%
9/9/2026UpgradeNeutral ➝ Buy$135.00 ➝ $260.00+23.19%
9/3/2026Boost TargetBuy$180.00 ➝ $235.00+9.48%
9/1/2026 DowngradeStrong-Buy ➝ Hold
8/31/2026 Reiterated RatingHold (C)
8/5/2026 DowngradeHold
8/3/2026Boost TargetHold$190.00 ➝ $205.000.00%
8/3/2026Boost TargetSell$95.00 ➝ $113.00-44.90%
7/31/2026Reiterated RatingMarket Perform$215.00+4.83%
7/31/2026Boost TargetOverweight$220.00 ➝ $230.00+14.36%
7/31/2026Boost TargetHold$192.00 ➝ $210.00+5.17%
7/31/2026Boost TargetBuy$155.00 ➝ $225.00+13.72%
7/6/2026 Reiterated RatingOutperform
5/14/2026 UpgradeNeutral ➝ Outperform$155.00+6.90%
2/6/2026Set Target$137.00+13.26%
8/4/2025 Set TargetOverweight$110.00+12.52%
8/4/2025Boost TargetEqual Weight$100.00 ➝ $105.00+8.45%
7/11/2025DowngradeSector Outperform ➝ Sector Perform$125.00+24.94%
2/28/2025DowngradeStrong-Buy ➝ Hold$100.00+18.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:41 PM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 8, 2026. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. recently released SpliceAI2, a new genomic AI model that helps researchers identify disease-relevant splice variants, which is a significant advancement for rare disease research and drug discovery that positions the company at the forefront of AI-driven genomics.
  • The company's stock is currently trading at $264.57, reflecting a strong upward trend from its 52-week low of $88.00, driven by its recent addition to the S&P 500 index which typically attracts significant demand from index-tracking funds.
  • Analysts from RBC Capital Markets have characterized Illumina's clinical sequencing revenue as a durable mid-teens growth opportunity, suggesting that the company has a stable and expanding revenue stream from a high-demand sector.
  • Illumina, Inc. has consistently beaten earnings expectations, reporting $1.31 in earnings per share for the most recent quarter against a consensus estimate of $1.23, demonstrating strong operational performance and profitability with a net margin of 18.36%.
  • The company has raised its full-year 2026 adjusted EPS guidance to $5.30–$5.40, indicating management confidence in continued growth and providing a solid fundamental foundation for the stock's valuation.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Despite the recent rally, the consensus rating from eighteen brokerages remains "Hold" with an average 12-month price objective of $219.69, which is significantly below the current stock price of $264.57, suggesting that the stock may be overvalued relative to analyst expectations.
  • Insider selling has been substantial, with Director Keith Meister selling over 119,000 shares in September 2026 alone, and insiders collectively selling over 2 million shares worth approximately $436 million in the last three months, which may signal a lack of confidence from those closest to the company.
  • Barclays has maintained an "underweight" rating on Illumina, Inc. with a price target of $200, arguing that current expectations and valuation have outpaced near-term fundamentals, indicating that the stock's recent gains may not be sustainable.
  • The company's P/E ratio of 51.99 is relatively high, which means investors are paying a premium for each dollar of earnings, and this elevated valuation could make the stock more vulnerable to price corrections if growth slows or market sentiment shifts.
  • Short interest has been increasing, with the number of shares shorted rising to over 10.5 million in the most recent reporting period, indicating that a significant portion of the market is betting against the stock's future performance.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $225.94, with a high forecast of $310.00 and a low forecast of $113.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted downside of -17.18% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 2 upgrades and 2 downgrades by analysts.

Analysts like Illumina more than other "healthcare" companies. The consensus rating score for Illumina is 2.44 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how ILMN compares to other companies.


MarketBeat monitors more than a dozen sources for Illumina analyst ratings, with the most recent rating issued on 10/13/2026.
From Our Partners